Published in Respiratory Therapeutics Week, December 12th, 2005
Results were presented at a poster session at the AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania.
As a single agent, talabostat caused a 35% greater reduction in tumor size than pemetrexed alone. Administration of 500 mg/kg of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.